Navigation Links
Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
Date:4/4/2008

forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully adjust our strategy and reduce our operating expenses in order to properly support the trials of our drug candidates; our ability to complete cost-effective clinical trials or meet anticipated the development timelines set forth above for the drug candidates in our pipeline, including Zerenex and KRX-0401; our ability to sell the $12 million of auction note securities in order to fund our operations; or other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

KERYX CONTACT:

Lauren Fischer

Director - Investor Relations

Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5965

E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
2. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
3. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
5. Keryx Biopharmaceuticals Announces Additions to Management Team
6. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
7. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
9. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
10. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
11. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... (PRWEB) September 30, 2014 ... solutions for drug discovery and related life ... consortium has chosen Genedata Selector as its ... (NGS) data. FUNGITECT is a European consortium ... fungal diseases via individualized anti-fungal drug therapies. ...
(Date:9/30/2014)... , Sept. 30, 2014  KemPharm, Inc., ... discovery and development of proprietary new molecular entity ... Patent and Trademark Office (USPTO) issued U.S. Patent ... entitled, "Benzoic Acid, Benzoic Acid Derivatives and Heteroaryl ... Making and Use Thereof." The patent, ...
(Date:9/30/2014)... MAR, Calif. , Sept. 30, 2014 ... for women,s health announces its receipt of a patent ... FemmyCycle menstrual cup has also received FDA clearance in ... Canada, and the CE in Europe. This patent is related ... conjunction with this issuance, the company is releasing FemmyCycle ...
(Date:9/30/2014)... The overall research objective was to ... and use. Most researchers outsource NGS technologies; however, ... within the next 12 months. Data accuracy and ... sequencing instruments. Disease-related research is the dominant use ... to surge, with half of the respondents planning ...
Breaking Biology Technology:FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2The FemmyCycle 2Global Next-generation Sequencing Trends 2
... GeneGo, Inc., the leading,systems biology tools company, announced ... Center of Excellence. MD Anderson researchers will have,institution-wide ... advanced support. MD Anderson specializes in cancer treatment ... clinical trials programs.,MetaCore will be used throughout many ...
... and VANCOUVER, Sept. 2 /PRNewswire-FirstCall/ - OncoGenex,Pharmaceuticals, ... the "Company") has,announced today that it has ... rights to develop and commercialize TOCOSOL(R),Paclitaxel. Under ... entitled to,receive royalty payments from future TOCOSOL ...
... EDISON, N.J., Sept. 1 PSKW, LLC, a ... the pharmaceutical,industry, announced today that it has significantly ... last year in the Supreme Court of the ... McKesson Specialty Arizona Inc.,("McKesson"), a wholly-owned subsidiary of ...
Cached Biology Technology:MD Anderson Becomes a GeneGo Center of Excellence Using MetaCore for Oncology Research 2OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals 2OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals 3PSKW Expands Its Lawsuit Against McKesson to Seek Assignment of McKesson's Patent Application 2
(Date:9/30/2014)... a suite of perilous threats in today,s ocean. ... climate change, fragile coral ecosystems are disappearing at ... some species of corals surrounding the island of ... in their tropical environment: coral guard-crabs. New research ... Marine Station scientist Seabird McKeon and the museum,s ...
(Date:9/29/2014)... species of gut bacteria called Clostridium ramosum , coupled ... The work is published this week in mBio , ... , A research team from the German Institute of ... gut bacteria including C. ramosum gained weight when ... C. ramosum were less obese even when consuming a ...
(Date:9/29/2014)... 1970 and 2010 populations of mammals, birds, reptiles, ... percent, says the 2014 Living Planet Report released ... loss occurs disproportionately in low-income countriesand correlates with ... In addition to the precipitous decline in wildlife ... signs about the overall health of the planet. ...
Breaking Biology News(10 mins):Smithsonian scientists discover coral's best defender against an army of sea stars 2Gut bacteria promote obesity in mice 2Half of global wildlife lost, says new WWF report 2
... chemotherapy for the treatment of skin cancer is one ... researchers successfully synthesized a natural substance that shows exceptional ... U of A chemistry professor Dennis Hall said after ... produced the substance called Palmerolide A. "The potency ...
... DigitalPersona, Inc., a leader in fingerprint identity ... a leading supplier of point-of-sale (POS) software for ... NextGen POS and Classic POS solutions. WAND,s quick-service ... cashier accountability and deter unauthorized manager overrides. ...
... the blink of a geologic eye global temperatures were ... come by. Today, the largest island in the world is covered ... hot spot for climate scientists. Why? Because tiny bubbles ... about global warming: how fast and how much will ice ...
Cached Biology News:WAND Point-of-Sale Solutions Integrate U.are.U(R) Fingerprint Biometrics From DigitalPersona for Quick-Service Restaurants 2WAND Point-of-Sale Solutions Integrate U.are.U(R) Fingerprint Biometrics From DigitalPersona for Quick-Service Restaurants 3As Greenland melts 2
...
N,N'-Methylene-bis-acrylamide, Ultra Pure...
... Serum; U.S. sourced, ideal for ... quality; Low hemoglobin; Endotoxin: < ... of US origin; U.S. sourced, ... an uncompromising quality. Low hemoglobin ...
NEWBORN CALF SERUM AND PLASMA...
Biology Products: